FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

5. Relationship of Reporting Person(s) to Issuer

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1/h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person*     Bernick Brian						2. Issuer Name <b>and</b> Ticker or Trading Symbol TherapeuticsMD, Inc. [ TXMD ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner  Officer (check title						
(Last) (First) (Middle) 6800 BROKEN SOUND PKWY NW, THIRD FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 09/12/2018									Officer (give title Other (specify below) below)						
(Street)	_ 4.	If Ame	ndme	nt, Date	e of Ori	iginal F	iled (Month/D		Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting												
(City)	(5	state)	(Zip)												Person						
		Tak	ole I -	Non-Der	ivativ	e Se	curit	ties A	cqui	red, [	Disposed	of, or	Benef	ficia	lly Owned						
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year		Execution Date,		ate,	3. Transaction Code (Instr. 8)				d (A) or r. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Nature lirect neficia vnersh str. 4)	al		
									Code V		Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(		
Common Stock			09/12/20	018				M		91,400	A	\$0.10	)18	6,648,771(1)		I	In E	By BF Investment Enterprises, Ltd.			
Common Stock		09/12/20	018	3			S <sup>(2)</sup>		91,400	D	\$6.25	5 <sup>(3)</sup>	6,557,371 <sup>(1)</sup>		) I		By BF Investment Enterprises, Ltd.				
Common	ommon Stock		09/13/2018		1			M		91,400	A	\$0.10	)18	6,648,771 <sup>(1)</sup>		I	In E	By BF Investment Enterprises, Ltd.			
Common Stock				09/13/2018					S <sup>(2)</sup>		91,400	D	\$6.34	15 <sup>(4)</sup>	6,557,371(1)		I		By BF Investment Enterprises, Ltd.		
Common	Stock							242,000		)	D										
Common Stock														3,000(5)		I		By BF Management, LLC			
			Table								sposed of				y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execu if any	Deemed 4. ution Date, Tra		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Insti 3, 4 and 5)		6. Date Ex Expiration (Month/Da		rcisable and Date	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		nount	Derivative Security	deriv Secu Bene Owne Follo Repo	rities eficially ed wing orted saction(s)	10. Owners Form: Direct (I or Indire (I) (Instr	nip o B O ct (I	1. Nature f Indirect deneficial dwnership nstr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable	Expiration Date	Title	or Nu of	mber	1 1						
Non- Qualified Stock Option (right to buy)	\$0.1018	09/12/2018			M	M 91,400		0 01/01/201		01/01/2019	Comn	mmon 91,400		\$0	1,37	71,510 <sup>(1)</sup>	I	I By Bi Invest Enter Ltd.			
Non- Qualified Stock Option (right to buy)	\$0.1018	09/13/2018			М			91,400	01/0	01/2012	01/01/2019	Comn		,400	\$0	1,28	30,110 <sup>(1)</sup>	I	Ir E	by BF nvestment interprises, itd.	
Explanatio	n of Respon	ses:			عمال ال	Tana /		Th - P		, Daves	(i) hald	ah au - 😂	hia				70 00/			DE	

with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

- 2. The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.15 to \$6.34, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.25 to \$6.43, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The reported securities are held by the GP. As disclosed in footnote 1 above, the Reporting Person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The Reporting Person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.

<u>/s/ Brian Bernick</u> 09/14/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.